In a significant development for its pharmaceutical division, Johnson & Johnson has secured U.S. regulatory approval for ICOTYDE™ (icotrokinra), a novel treatment for moderate-to-severe plaque psoriasis. The U.S. Food and Drug Administration (FDA) clearance marks a milestone as the therapy is the world’s first oral peptide designed to selectively block the IL-23 receptor, a key pathway implicated in inflammatory autoimmune conditions.
Clinical Performance and Strategic Timing
The approval is underpinned by the robust ICONIC clinical program, which encompassed four Phase 3 trials involving approximately 2,500 patients. Data from these studies demonstrated compelling efficacy: around 70% of participants achieved clear or almost clear skin after 16 weeks. Furthermore, 55% attained a PASI-90 response, a stringent dermatological benchmark for skin clearance. The drug’s safety profile remained consistent and stable through 52 weeks, with no new safety signals identified.
Johnson & Johnson is commercializing ICOTYDE in collaboration with its partner, Protagonist Therapeutics. The therapy is indicated for adults and adolescents aged twelve years and older who are candidates for systemic therapy or phototherapy.
This regulatory success arrives at an opportune moment for J&J’s Innovative Medicine segment, as the healthcare conglomerate sharpens its strategic focus on high-growth pharmaceutical assets. The company’s shares are currently trading just 2% below their 52-week high of 212.65 euros.
Should investors sell immediately? Or is it worth buying Johnson & Johnson?
Concurrent Corporate Developments
Alongside this pipeline advancement, other notable events are shaping the company’s near-term outlook. A California court recently overturned punitive damage claims in a talcum powder litigation, providing a meaningful reduction in short-term legal risk exposure for Johnson & Johnson. It is important to note that compensatory damage claims remain, and the company has stated its intention to appeal the ruling.
On the financial front, Johnson & Johnson’s board has authorized another increase in its dividend, a move supported by the firm’s strong free cash flow generation. As part of an ongoing portfolio refinement strategy, the company is also divesting its minority stakes in several biotechnology partners.
The convergence of a groundbreaking drug approval, favorable legal developments, and shareholder-friendly capital allocation underscores a period of strategic execution for Johnson & Johnson as it navigates its evolving business landscape.
Ad
Johnson & Johnson Stock: Buy or Sell?! New Johnson & Johnson Analysis from March 27 delivers the answer:
The latest Johnson & Johnson figures speak for themselves: Urgent action needed for Johnson & Johnson investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 27.
Johnson & Johnson: Buy or sell? Read more here...
